YD Bio (YDES) Operating Leases (2024)
YD Bio (YDES) posted quarterly Operating Leases of $5.7 billion for Q4 2024.
YD Bio (YDES) Operating Leases (2024) Analysis & Trends
YD Bio (YDES) has reported Operating Leases for 1 consecutive years, with $5.7 billion the latest figure, recorded in Q4 2024.
- In Q4 2024, Operating Leases changed N/A year-over-year to $5.7 billion; the TTM figure through Dec 2024 stood at $5.7 billion (changed N/A YoY), while the FY2024 annual figure was $5.7 billion, changed N/A from the prior year.
- Operating Leases was little changed at $5.7 billion in Q4 2024 per YDES's latest filing.
- Across five years, Operating Leases topped out at $5.7 billion in Q4 2024 and bottomed at $5.7 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | YD Bio | 319.58 Mn | 313.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.68 Bn |